IRIS
CASCINU, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.578
EU - Europa 7.991
AS - Asia 6.492
SA - Sud America 2.185
AF - Africa 359
Continente sconosciuto - Info sul continente non disponibili 176
OC - Oceania 6
Totale 32.787
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.342
SG - Singapore 2.007
RU - Federazione Russa 1.902
BR - Brasile 1.726
VN - Vietnam 1.463
UA - Ucraina 1.383
IT - Italia 867
CN - Cina 786
IE - Irlanda 695
DE - Germania 691
TR - Turchia 640
SE - Svezia 627
HK - Hong Kong 567
DK - Danimarca 542
FR - Francia 444
FI - Finlandia 391
KR - Corea 288
GB - Regno Unito 231
AR - Argentina 157
BD - Bangladesh 153
IN - India 137
CI - Costa d'Avorio 124
CA - Canada 89
EC - Ecuador 83
ID - Indonesia 82
IQ - Iraq 82
MX - Messico 77
MA - Marocco 66
ZA - Sudafrica 62
CO - Colombia 61
NL - Olanda 44
VE - Venezuela 44
JP - Giappone 41
CL - Cile 39
PK - Pakistan 33
BE - Belgio 31
PH - Filippine 30
PL - Polonia 30
ES - Italia 28
UZ - Uzbekistan 28
PY - Paraguay 27
KE - Kenya 22
DZ - Algeria 21
PE - Perù 21
MY - Malesia 20
TN - Tunisia 20
UY - Uruguay 19
EG - Egitto 18
SA - Arabia Saudita 18
AE - Emirati Arabi Uniti 14
CR - Costa Rica 14
RO - Romania 12
DO - Repubblica Dominicana 11
EU - Europa 11
AL - Albania 10
AZ - Azerbaigian 10
AT - Austria 9
HN - Honduras 9
JM - Giamaica 9
KZ - Kazakistan 9
JO - Giordania 8
BG - Bulgaria 7
IL - Israele 7
LT - Lituania 7
NP - Nepal 7
OM - Oman 7
PA - Panama 7
RS - Serbia 7
BH - Bahrain 6
LB - Libano 6
TH - Thailandia 6
CZ - Repubblica Ceca 5
ET - Etiopia 5
KG - Kirghizistan 5
NI - Nicaragua 5
TW - Taiwan 5
GY - Guiana 4
IR - Iran 4
MD - Moldavia 4
PS - Palestinian Territory 4
QA - Qatar 4
SC - Seychelles 4
TT - Trinidad e Tobago 4
AU - Australia 3
BA - Bosnia-Erzegovina 3
CH - Svizzera 3
GE - Georgia 3
GR - Grecia 3
KW - Kuwait 3
LY - Libia 3
NG - Nigeria 3
PR - Porto Rico 3
SN - Senegal 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
AO - Angola 2
BO - Bolivia 2
BS - Bahamas 2
EE - Estonia 2
GT - Guatemala 2
Totale 32.590
Salva come PNG Salva come JPEG
Città #
Ashburn 2.514
Dallas 1.923
Jacksonville 1.398
Singapore 1.159
Fairfield 1.025
Chandler 756
Dublin 693
Boardman 672
Wilmington 551
Hong Kong 549
San Jose 451
Ho Chi Minh City 447
Woodbridge 423
Council Bluffs 401
Houston 401
Seattle 373
Hanoi 333
New York 324
The Dalles 323
San Mateo 281
Lawrence 279
Princeton 279
Cambridge 273
Moscow 237
Lauterbourg 236
Ann Arbor 220
Beijing 212
Centro 206
Los Angeles 174
Des Moines 161
Hefei 149
São Paulo 147
Abidjan 123
San Diego 123
Milan 114
Buffalo 73
Chicago 73
Helsinki 73
Munich 73
Da Nang 72
Haiphong 64
London 53
Rio de Janeiro 53
Santa Clara 51
Orem 50
Turin 50
Turku 41
Miano 37
Porto Alegre 37
Brasília 36
Belo Horizonte 34
Tokyo 34
Montreal 33
Guayaquil 31
Biên Hòa 30
Frankfurt am Main 30
Hải Dương 29
Chennai 28
Johannesburg 28
Baghdad 27
Stockholm 26
Brussels 25
Curitiba 25
Tashkent 25
Rome 24
Warsaw 24
Ninh Bình 23
Campinas 22
Marche 22
Norwalk 22
Quito 22
Thái Bình 22
Brooklyn 21
Dhaka 21
Fortaleza 21
Manchester 21
Shanghai 21
Denver 20
Kilburn 20
Nairobi 20
Phoenix 20
Santiago 20
Guangzhou 19
Washington 19
Bogotá 17
Can Tho 17
Columbus 17
Montevideo 17
Mumbai 17
Pune 17
Boston 16
Guarulhos 16
Izmir 16
Amsterdam 15
Lima 15
Paris 15
San Francisco 15
Cape Town 14
Casablanca 14
Poplar 14
Totale 19.847
Salva come PNG Salva come JPEG
Nome #
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 2.290
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. 225
Anemia may influence the outcome of patients undergoing neoadjuvant treatment for rectal cancer 221
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 200
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: A multicentric retrospective analysis 196
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 195
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 195
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies 194
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 184
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma 183
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. 182
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 182
A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. 177
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 175
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 170
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. 170
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 169
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 168
Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. 167
A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. 167
A cost-benefit analysis of chemotherapy for gastric cancer. 166
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 164
Neutrophil‑to‑lymphocyte ratio may be associated with the outcome in patients with prostate cancer 161
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 160
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 158
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 158
A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 157
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 156
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 156
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target 153
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 151
Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 150
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 150
Panitumumab for the treatment of metastatic colorectal cancer: A review 150
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 149
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. 148
Angiogenetic pathway as a therapeutic target in renal cell carcinoma. 148
Translational challenges from the 2014 Gastrointestinal Cancers Symposium: Toward a true tailored therapy through effective research 147
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 145
Trattamento del carcinoma del pancreas. Attualità e prospettive 145
Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment. 145
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. 144
New target therapies in advanced pancreatic cancer. 143
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 143
Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. 143
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 142
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy 141
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 141
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. 140
Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. 139
Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen. 139
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 138
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. 138
Progress of molecular targeted therapies for advanced renal cell carcinoma. 138
Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity. 137
c-erbB-2 and common prognostic factors in breast cancer patients. 136
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 135
Pain and its treatment in hospitalized patients with metastatic cancer. 134
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 134
A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. 133
A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 133
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 133
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer 133
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. 133
A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. 132
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 132
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 130
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. 129
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 129
Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes. 129
Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 128
Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. 128
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 128
Transient sunitinib resistance in gastrointestinal stromal tumors. 128
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. 126
A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 126
Locoregional treatments of unresectable liver metastases from colorectal cancer. 126
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 126
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib 126
A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. 125
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 125
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. 124
A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. 124
5-Fluorouracil, leucovorin and interferon alpha 2b in advanced pancreatic cancer: a pilot study. 124
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors 122
Selecting the best treatment for an individual patient. 121
Recombinant human erythropoietin in chemotherapy-associated anemia. 120
Escalating dose of tegafur combined with oral etoposide in metastatic gastric carcinoma. 120
Palliative treatment 120
P-CHOP: cisplatin (P) added to the standard CHOP regimen as first-line treatment for aggressive non-Hodgkin lymphoma: a single-institution phase II study. 119
Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: It is not about the destination, it is about the journey 119
Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. 118
The challenge of targeted therapies for gastric cancer patients: The beginning of a long journey 118
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. 118
Cancer of pancreas. 117
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 117
A randomized, double blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel. 115
Role of STAT3 pathway in genitourinary tumors 114
Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. 113
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. 113
Totale 16.626
Salva come PNG Salva come JPEG
Categoria #
all - tutte 149.974
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 149.974
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.818 0 522 16 69 19 147 71 128 131 207 128 380
2022/20232.713 308 301 215 168 191 322 3 123 837 13 181 51
2023/20241.733 327 31 73 351 320 324 35 34 0 27 15 196
2024/20253.893 386 340 189 27 131 55 337 140 1.099 420 352 417
2025/202613.304 567 1.198 1.884 1.651 1.012 747 1.699 1.175 1.657 980 244 490
2026/2027816 523 293 0 0 0 0 0 0 0 0 0 0
Totale 32.787